The Therapeutic Promise of Mesenchymal Stem Cells for Liver Restoration

Trends in Molecular Medicine

Volumn 21, Issue 11, 2015, Pages 673-686

  Christ, Bruno ^a   Brückner, Sandra ^a   Winkler, Sandra ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Differentiation; Hepatocyte; Liver disease; Stem cell therapy

Indexed keywords

ADIPOCYTOKINE; CARBON TETRACHLORIDE; CYTOKINE; HUMORAL ANTIBODY; PARACETAMOL; THIOACETAMIDE;

ACUTE LIVER FAILURE; ATTENUATION; CELL COMMUNICATION; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; HEPATOCYTE TRANSPLANTATION; HUMAN; IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; LIVER; LIVER CELL; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER REGENERATION; LIVER RESECTION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLEIOTROPY; PORTAL VEIN; REVIEW; ANIMAL; CYTOLOGY; LIVER DISEASES; MESENCHYMAL STROMA CELL; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; HEPATOCYTES; HUMANS; LIVER; LIVER DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84947557034     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.09.004     Document Type: Review

References (109)

1. Forbes S.J., et al. Cell therapy for liver disease: from liver transplantation to cell factory. J. Hepatol. 2015, 62:S157-S169.
2. Cantz T., et al. Concise review: cell therapies for hereditary metabolic liver diseases - concepts, clinical results, and future developments. Stem Cells 2015, 33:1055-1062.
3. Christ B., Pelz S. Implication of hepatic stem cells in functional liver repopulation. Cytometry Part A 2013, 83A:90-102.
4. Wallace M.C., et al. Emerging and disease-specific mechanisms of hepatic stellate cell activation. Semin. Liver Dis. 2015, 35:107-118.
5. Yin C., et al. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Invest. 2013, 123:1902-1910.
6. Best J., et al. Role of liver progenitors in liver regeneration. Hepatobiliary Surg. Nutr. 2015, 4:48-58.
7. Marra F., Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr. Pharm. Des. 2013, 19:5250-5269.
8. Angulo P., et al. Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin. Liver Dis. 2015, 35:132-145.
9. Chen M., et al. Drug-Induced liver injury: interactions between drug properties and host factors. J. Hepatol. 2015, 63:503-514.
10. Michalopoulos G.K. Liver regeneration after partial hepatectomy. Am. J. Pathol. 2010, 176:2-13.
11. Boulter L., et al. Differentiation of progenitors in the liver: a matter of local choice. J. Clin. Invest. 2013, 123:1867-1873.
12. Diehl A.M., Chute J. Underlying potential: cellular and molecular determinants of adult liver repair. J. Clin. Invest. 2013, 123:1858-1860.
13. Kordes C., et al. Hepatic stellate cells contribute to progenitor cells and liver regeneration. J. Clin. Invest. 2014, 124:5503-5515.
14. Kordes C., et al. Hepatic stellate cells support hematopoiesis and are liver-resident mesenchymal stem cells. Cell. Physiol. Biochem. 2013, 31:290-304.
15. Michelotti G.A., et al. Smoothened is a master regulator of adult liver repair. J. Clin. Invest. 2013, 123:2380-2394.
16. Meier R.P.H., et al. Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?. Stem Cell Res. 2013, 11:1348-1364.
17. Liu W-H., et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J. Cell. Mol. Med. 2015, 19:511-520.
18. Christ B., Stock P. Stem cell-derived hepatocytes for functional liver replacement. Front. Immunol. 2012, 3:168.
19. Castro-Manrreza M.E., Montesinos J.J. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J. Immunol. Res. 2015, 2015:394917.
20. Le Blanc K., Davies L.C. Mesenchymal stromal cells and the innate immune response. Immunol. Lett. 2015, Published online May 14, 2015. 10.1016/j.imlet.2015.05.004.
21. Minteer D.M., et al. Adipose stem cells: biology, safety, regulation, and regenerative potential. Clin. Plast. Surg. 2015, 42:169-179.
22. Kfoury Y., Scadden D.T. Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell 2015, 16:239-253.
23. Fox I.J., et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N. Engl. J. Med. 1998, 338:1422-1427.
24. Ribes-Koninckx C., et al. Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases. Cell Transplant. 2012, 21:2267-2282.
25. Puppi J., et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in london. Cell Transplant. 2012, 21:1-10.
26. Hughes R.D., et al. Current status of hepatocyte transplantation. Transplantation 2012, 93:342-347.
27. Viswanathan P., Gupta S. New directions for cell-based therapies in acute liver failure. J. Hepatol. 2012, 57:913-915.
28. Banas A., et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J. Gastroenterol. Hepatol. 2009, 24:70-77.
29. Aurich H., et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 2009, 58:570-581.
30. Lysy P.A., et al. Persistence of a chimerical phenotype after hepatocyte differentiation of human bone marrow mesenchymal stem cells. Cell Prolif. 2008, 41:36-58.
31. Stock P., et al. Hepatocytes derived from adult stem cells. Transplant. Proc. 2008, 40:620-623.
32. De Kock J., et al. Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential. Stem Cells Dev. 2012, 21:3309-3323.
33. Li J., et al. Transcriptional profiling and hepatogenic potential of acute hepatic failure-derived bone marrow mesenchymal stem cells. Differentiation 2010, 80:166-174.
34. Yovchev M.I., et al. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology 2014, 59:284-295.
35. Ma H.C., et al. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration. World J. Gastroenterol. 2014, 20:14884-14894.
36. + cells in rats with acute liver failure. Dig. Dis. Sci. 2010, 55:285-291.
37. Deng C., et al. Up-regulation of CXCR4 in rat umbilical mesenchymal stem cells induced by serum from rat with acute liver failure promotes stem cells migration to injured liver tissue. Mol. Cell. Biochem. 2014, 396:107-116.
38. Xie J., et al. Notch signaling regulates CXCR4 expression and the migration of mesenchymal stem cells. Cell. Immunol. 2013, 281:68-75.
39. Stock P., et al. Human bone marrow mesenchymal stem cell-derived hepatocytes improve the mouse liver after acute acetaminophen intoxication by preventing progress of injury. Int. J. Mol. Sci. 2014, 15:7004-7028.
40. Winkler S., et al. Mouse white adipose tissue-derived mesenchymal stem cells gain pericentral and periportal hepatocyte features after differentiation in vitro, which are preserved in vivo after hepatic transplantation. Acta Physiol. 2015, 215:89-104.
41. Zheng G., et al. Mesenchymal stromal cells affect disease outcomes via macrophage polarization. Stem Cells Int. 2015, 2015:11.
42. Eggenhofer E., et al. The life and fate of mesenchymal stem cells. Front. Immunol. 2014, 5:1-6.
43. Kadota Y., et al. Mesenchymal stem cells support hepatocyte function in engineered liver grafts. Organogenesis 2014, 10:268-277.
44. Wang Y., et al. Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates. Hepatology 2010, 52:1443-1454.
45. Fouraschen S.G., et al. Support of hepaticr by trophic factors from liver-derived mesenchymal stromal/stem cells. Animal Models for Stem Cell Therapy 2014, 89-104. Springer, New York. B. Christ (Ed.).
46. Parekkadan B., et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2007, 363:247-252.
47. Zhao W., et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J. Gastroenterol. 2012, 18:1048-1058.
48. Kim M-D., et al. Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis. Exp. Mol. Med. 2014, 46:e110.
49. Lin H., et al. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell. Mol. Immunol. 2011, 8:19-22.
50. Lavoie J.R., Rosu-Myles M. Uncovering the secretes of mesenchymal stem cells. Biochimie 2013, 95:2212-2221.
51. Jungermann K., Katz N. Functional specialization of different hepatocyte populations. Physiol. Rev. 1989, 69:708-764.
52. Gebhardt R., Hovhannisyan A. Organ patterning in the adult stage: the role of Wnt/β-catenin signaling in liver zonation and beyond. Dev. Dynamics 2010, 239:45-55.
53. Laconi E., et al. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am. J. Pathol. 1998, 153:319-329.
54. Koenig S., et al. Zonal expression of hepatocytic marker enzymes during liver repopulation. Histochem. Cell Biol. 2007, 128:105-114.
55. Goto Y., et al. Hepatocyte transplantation through the hepatic vein: a new route of cell transplantation to the liver. Cell Transplant. 2011, 20:1259-1270.
56. Gupta S., et al. Position-specific gene expression in the liver lobule is directed by the microenvironment and not by the previous cell differentiation state. J. Biol. Chem. 1999, 274:2157-2165.
57. Salomone F., et al. Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury. Stem Cell Res. 2013, 11:1037-1044.
58. Forbes S.J., Newsome P.N. New horizons for stem cell therapy in liver disease. J. Hepatol. 2012, 56:496-499.
59. Monga S.S. Role and regulation of β-catenin signaling during physiological liver growth. Gene Exp. 2014, 16:51-62.
60. Gebhardt R., Matz-Soja M. Liver zonation: novel aspects of its regulation and its impact on homeostasis. World J. Gastroenterol. 2014, 20:8491-8504.
61. Colletti M., et al. Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. Gastroenterology 2009, 137:660-672.
62. Fausto N., et al. Liver regeneration. J. Hepatol. 2012, 57:692-694.
63. Tautenhahn H-M., et al. Attenuation of postoperative acute liver failure by mesenchymal stem cell treatment due to metabolic implications. Ann. Surg. 2015, Published online March 13, 2015. 10.1097/sla.0000000000001155.
64. Lee Y.A., et al. Pathobiology of liver fibrosis: a translational success story. Gut 2015, 64:830-841.
65. Parekkadan B., et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007, 2:e941.
66. Yi T., Song S. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch. Pharm. Res. 2012, 35:213-221.
67. Prockop D.J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 2013, 31:2042-2046.
68. Ji A.T-Q., et al. Niche-dependent regulations of metabolic balance in high-fat diet-induced diabetic mice by mesenchymal stromal cells. Diabetes 2015, 64:926-936.
69. Li J., et al. Return of the metabolic trajectory to the original area after human bone marrow mesenchymal stem cell transplantation for the treatment of fulminant hepatic failure. J. Proteome Res. 2012, 11:3414-3422.
70. Ma X-R., et al. Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials. Gastroenterol. Res. Prac. 2015, 2015:10.
71. -/- mice via Th1 response and matrix metalloproteinase activity. Gut 2012, 61:907-916.
72. Muraca M. Evolving concepts in cell therapy of liver disease and current clinical perspectives. Dig. Liver Dis. 2011, 43:180-187.
73. Iwamoto T., et al. Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice. Cell Tissue Res. 2013, 351:487-495.
74. Huang C-K., et al. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology 2013, 57:1550-1563.
75. Schattenberg J.M., Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr. Opin. Lipidol. 2011, 22:479-488.
76. Anstee Q.M., et al. How big a problem is non-alcoholic fatty liver disease?. Br. Med. J. 2011, 343:d3897.
77. Vonghia L., et al. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int. J. Mol. Sci. 2013, 14:19867-19890.
78. Jin C., et al. Innate immune receptors: key regulators of metabolic disease progression. Cell Metab. 2013, 17:873-882.
79. Ramadori G., Christ B. Cytokines and the hepatic acute-phase response. Semin. Liver Dis. 1999, 19:141-155.
80. Bian Z., Ma X. Liver fibrogenesis in non-alcoholic steatohepatitis. Front. Physiol. 2012, 3:248.
81. Kammoun H.L., et al. Nutritional related liver disease: targeting the endoplasmic reticulum stress. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:575-582.
82. Mollica M.P., et al. From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutr. Metab. Cardiovasc. Dis. 2011, 21:222-230.
83. Winkler S., et al. Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model. Exp. Cell Res. 2014, 326:230-239.
84. Pelz S., et al. A methionine-choline-deficient diet elicits NASH in the immunodeficient mouse featuring a model for hepatic cell transplantation. Exp. Cell Res. 2012, 318:276-287.
85. Friedman S.L. Hepatic fibrosis - overview. Toxicology 2008, 254:120-129.
86. Alisi A., et al. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology 2011, 54:1500-1502.
87. Li L., et al. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
88. Guglielmi A., et al. How much remnant is enough in liver resection?. Dig. Surg. 2012, 29:6-17.
89. Huang J., Rudnick D.A. Elucidating the metabolic regulation of liver regeneration. Am. J. Pathol. 2014, 184:309-321.
90. Jin X., et al. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 2007, 46:802-812.
91. Hamano M., et al. Lipid overloading during liver regeneration causes delayed hepatocyte DNA replication by increasing ER stress in mice with simple hepatic steatosis. J. Gastroenterol. 2014, 49:305-316.
92. Ezzat T.M., et al. Use of hepatocyte and stem cells for treatment of post-resectional liver failure: are we there yet?. Liver Int. 2011, 31:773-784.
93. Yu J., et al. Hypoxia preconditioned bone marrow mesenchymal stem cells promote liver regeneration in a rat massive hepatectomy model. Stem Cell Res. Ther. 2013, 4:83.
94. Hagen T.M., et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:1870-1875.
95. Pillich R.T., et al. Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-L-carnitine to mouse fibroblasts in culture. Exp. Cell Res. 2005, 306:1-8.
96. Christ B., Dollinger M.M. The generation of hepatocytes from mesenchymal stem cells and engraftment into the liver. Curr. Opin. Organ Transplant. 2011, 16:69-75.
97. Arnous S., et al. Bone marrow mononuclear cells and acute myocardial infarction. Stem Cell Res Ther. 2012, 3:2.
98. Bara J.J., et al. Concise review: bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells 2014, 32:1713-1723.
99. Rennert R.C., et al. Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. Stem Cell Res. Ther. 2014, 5:1-12.
100. Li B., et al. Mesenchymal stem cells mitigate cirrhosis through BMP7. Cell. Physiol. Biochem. 2015, 35:433-440.
101. Meier R.P.H., et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J. Hepatol. 2015, 62:634-641.
102. Chen X., et al. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis. 2014, 5:e1009.
103. Pan R-L., et al. Delta-like 1 serves as a new target and contributor to liver fibrosis down-regulated by mesenchymal stem cell transplantation. J. Biol. Chem. 2011, 286:12340-12348.
104. Fouraschen S.M.G., et al. Secreted factors of human liver-derived mesenchymal stem cells promote liver regeneration early after partial hepatectomy. Stem Cells Dev. 2012, 21:2410-2419.
105. Liu Z., et al. Human umbilical cord mesenchymal stromal cells rescue mice from acetaminophen-induced acute liver failure. Cytotherapy 2014, 16:1207-1219.
106. Ryu K-H., et al. Tonsil-derived mesenchymal stem cells alleviate concanavalin A-induced acute liver injury. Exp. Cell Res. 2014, 326:143-154.
107. Zhang Y., et al. Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells. Hepatology 2014, 59:671-682.
108. Zagoura D.S., et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 2012, 61:894-906.
109. Ezquer M., et al. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome. J. Hepatol. 2011, 55:1112-1120.